1.Identification of a new lamin A/C mutation in a chinese family affected with atrioventricular block as the prominent phenotype.
Xiaoyan, WU ; Qing K, WANG ; Le, GUI ; Mugen, LIU ; Xianqin, ZHANG ; Runming, JIN ; Wei, LI ; Lu, YAN ; Rong, DU ; Qiufen, WANG ; Jianfang, ZHU ; Junguo, YANG
Journal of Huazhong University of Science and Technology (Medical Sciences) 2010;30(1):103-7
Even though mutations in LMNA have been reported in patients with typical dilated cardiomyopathy (DCM) and atrioventricular block (AVB) previously, the purpose of this study was to disclose this novel genetic abnormality in one Chinese family with the atypical phenotype of progressive AVB followed by DCM with normal QRS interval. Genome-wide linkage analysis mapped the AVB gene in this family to a marker at chromosome 1q21.2, where the LMNA gene was located. Direct DNA sequence analysis revealed a heterozygous G to A transition at nucleotide 244 in exon 1 of LMNA, which resulted in an E82K mutation. The E82K mutation co-segregated with all affected individuals in the family, and was not present in 200 normal controls. Further clinical evaluation of mutation carriers showed that 5 of 6 AVB patients exhibited mild DCM with a late onset of age in the fourth and fifth decades. Ejection fractions were documented in 5 patients with DCM, but 4 showed a normal value of [Symbol: see text]50%. Echocardiography showed that atrial dilatation occurred earlier than ventricular dilatation in the patients. This study suggests that progressive AVB with normal QRS interval and accompanying DCM at later stages may represent a distinct type of DCM. The molecular mechanism by which the E82K mutation causes AVB as the prominent phenotype in DCM may be a focus of future studies.
2.Identification of Env-specific monoclonal antibodies from Chinese HIV-1 infected person by B cell activation and RT-PCR cloning.
Hui-Min WANG ; Ke XU ; Shuang-Qing YU ; Lin-Lin DING ; Hai-Yan LUO ; Robin FLINKO ; George K LEWIS ; Xia FENG ; Ji-Rong SHAO ; Yong-Jun GUAN ; Yi ZENG
Chinese Journal of Virology 2012;28(4):358-365
To obtain protective human monoclonal antibody from HIV-1 infected person, we adapted a technology for isolating antigen specific monoclonal antibody from human memory B cells through in vitro B cell activation coupled with RT-PCT and expression cloning. Human B cells were purified by negative sorting from PBMCs of HIV-1 infected individuals and memory B cells were further enriched using anti-CD27 microbeads. Two hundred memory B cells per well were cultured in 96-well round-bottom plates Env-specific antibodies in supernatants were with feeder cells in medium containing EBV and CpG. screened by ELISA after 1-2 weeks' culture. Cells from positive wells of Env-specific antibody were harvested and total RNA was isolated. Human VH and Vkappa or Vlambda genes were amplified by RT-PCR and cloned into IgG1 and kappa or lambda expressing vectors. Functional VH and Vkappa or Vlambda were identified by cotransfecting 293T cells with individual heavy chain and light chain clones followed by analysis of culture supernatants by ELISA for Env-specific antibodies. Finally, corresponding mAb was produced by transient transfection of 293T cells with the identified VH and Vkappa/lambda pair and purified by protein A affinity chromatography. Purified monocolonal antibodies were used for HIV-1 specific antibody-dependent cell-mediated cytotoxicity (ADCC) and neutralizing activity assay. Four monocolonal Env-specific antibodies were isolated from one HIV-1 subtype B' infected individual. Two of them showed strong ADCC activity and one showed weak neutralizing activity against HIV-1. Its further studies on their application in therapeutic or prophylactic vaccines against HIV-1 should be grounded.
Antibodies, Monoclonal
;
genetics
;
immunology
;
Antibody Specificity
;
Asian Continental Ancestry Group
;
B-Lymphocytes
;
immunology
;
Cloning, Molecular
;
HEK293 Cells
;
HIV Infections
;
blood
;
immunology
;
HIV-1
;
immunology
;
pathogenicity
;
Humans
;
Immunity, Humoral
;
Neutralization Tests
;
Polymerase Chain Reaction
;
env Gene Products, Human Immunodeficiency Virus
;
immunology